The Apex Times
Above the Noise
Business Wire
BusinessMarket commentary weighs Airbnb profitability and low leverage against PepsiCo’s steadier margins, but flags valuation as the swing factor for 2026The Apex TimesBusinessJPMorgan Chase shares get lift in focus after analysts revise fair value estimates higherThe Apex TimesBusinessBoeing shares climb 7.4% year-to-date as deliveries and backlog remain in focusThe Apex TimesBusinessHome Depot CEO Ted Decker starts temporary medical leave, company expects return soonThe Apex TimesBusinessPalantir’s valuation premium hinges on how long US “sovereign AI” demand lasts, market analysis saysThe Apex TimesBusinessCoinbase swept into New York’s widening probe of prediction markets as CFTC opposition enters the disputeThe Apex TimesBusinessNVIDIA CEO Jensen Huang ranks No. 1 on Glassdoor’s Best CEOs list for 2026The Apex TimesBusinessPalantir, Microsoft slip as market rotates from software to chips and network infrastructureThe Apex TimesBusinessBank of America to acquire MDSec, adding cybersecurity specialists as banks lean into AI and digital channelsThe Apex TimesBusinessCoca-Cola’s premium valuation puts scrutiny on whether recent gains are sustainableThe Apex TimesBusinessIntel and Qualcomm Compete for Investors as AI-PC Momentum Meets Valuation DebateThe Apex TimesBusinessGoldman Sachs to buy NEOS Investments’ ETF business in $2.25 billion deal, aiming to expand active ETF footprintThe Apex TimesBusinessMarket commentary weighs Airbnb profitability and low leverage against PepsiCo’s steadier margins, but flags valuation as the swing factor for 2026The Apex TimesBusinessJPMorgan Chase shares get lift in focus after analysts revise fair value estimates higherThe Apex TimesBusinessBoeing shares climb 7.4% year-to-date as deliveries and backlog remain in focusThe Apex TimesBusinessHome Depot CEO Ted Decker starts temporary medical leave, company expects return soonThe Apex TimesBusinessPalantir’s valuation premium hinges on how long US “sovereign AI” demand lasts, market analysis saysThe Apex TimesBusinessCoinbase swept into New York’s widening probe of prediction markets as CFTC opposition enters the disputeThe Apex TimesBusinessNVIDIA CEO Jensen Huang ranks No. 1 on Glassdoor’s Best CEOs list for 2026The Apex TimesBusinessPalantir, Microsoft slip as market rotates from software to chips and network infrastructureThe Apex TimesBusinessBank of America to acquire MDSec, adding cybersecurity specialists as banks lean into AI and digital channelsThe Apex TimesBusinessCoca-Cola’s premium valuation puts scrutiny on whether recent gains are sustainableThe Apex TimesBusinessIntel and Qualcomm Compete for Investors as AI-PC Momentum Meets Valuation DebateThe Apex TimesBusinessGoldman Sachs to buy NEOS Investments’ ETF business in $2.25 billion deal, aiming to expand active ETF footprintThe Apex TimesBusinessMarket commentary weighs Airbnb profitability and low leverage against PepsiCo’s steadier margins, but flags valuation as the swing factor for 2026The Apex TimesBusinessJPMorgan Chase shares get lift in focus after analysts revise fair value estimates higherThe Apex TimesBusinessBoeing shares climb 7.4% year-to-date as deliveries and backlog remain in focusThe Apex TimesBusinessHome Depot CEO Ted Decker starts temporary medical leave, company expects return soonThe Apex TimesBusinessPalantir’s valuation premium hinges on how long US “sovereign AI” demand lasts, market analysis saysThe Apex TimesBusinessCoinbase swept into New York’s widening probe of prediction markets as CFTC opposition enters the disputeThe Apex TimesBusinessNVIDIA CEO Jensen Huang ranks No. 1 on Glassdoor’s Best CEOs list for 2026The Apex TimesBusinessPalantir, Microsoft slip as market rotates from software to chips and network infrastructureThe Apex TimesBusinessBank of America to acquire MDSec, adding cybersecurity specialists as banks lean into AI and digital channelsThe Apex TimesBusinessCoca-Cola’s premium valuation puts scrutiny on whether recent gains are sustainableThe Apex TimesBusinessIntel and Qualcomm Compete for Investors as AI-PC Momentum Meets Valuation DebateThe Apex TimesBusinessGoldman Sachs to buy NEOS Investments’ ETF business in $2.25 billion deal, aiming to expand active ETF footprintThe Apex TimesBusinessMarket commentary weighs Airbnb profitability and low leverage against PepsiCo’s steadier margins, but flags valuation as the swing factor for 2026The Apex TimesBusinessJPMorgan Chase shares get lift in focus after analysts revise fair value estimates higherThe Apex TimesBusinessBoeing shares climb 7.4% year-to-date as deliveries and backlog remain in focusThe Apex TimesBusinessHome Depot CEO Ted Decker starts temporary medical leave, company expects return soonThe Apex TimesBusinessPalantir’s valuation premium hinges on how long US “sovereign AI” demand lasts, market analysis saysThe Apex TimesBusinessCoinbase swept into New York’s widening probe of prediction markets as CFTC opposition enters the disputeThe Apex TimesBusinessNVIDIA CEO Jensen Huang ranks No. 1 on Glassdoor’s Best CEOs list for 2026The Apex TimesBusinessPalantir, Microsoft slip as market rotates from software to chips and network infrastructureThe Apex TimesBusinessBank of America to acquire MDSec, adding cybersecurity specialists as banks lean into AI and digital channelsThe Apex TimesBusinessCoca-Cola’s premium valuation puts scrutiny on whether recent gains are sustainableThe Apex TimesBusinessIntel and Qualcomm Compete for Investors as AI-PC Momentum Meets Valuation DebateThe Apex TimesBusinessGoldman Sachs to buy NEOS Investments’ ETF business in $2.25 billion deal, aiming to expand active ETF footprintThe Apex Times
Back to front
Eli Lilly files six more lawsuits tied to retatrutide black-market sales, as CMO warns the pills are not legitimate medicines
The Apex Times

THE APEX TIMES

Business/The Apex Times/Aug 12, 8:55 AM EDT

Eli Lilly files six more lawsuits tied to retatrutide black-market sales, as CMO warns the pills are not legitimate medicines

The drugmaker says newly targeted sellers are offering products that are unverified and unapproved, and it is stepping up legal action aimed at limiting off-channel distribution of retatrutide.

2 min readEditor-approved Apex article

Eli Lilly is taking additional legal steps aimed at what it describes as illegal sales of retatrutide outside approved channels. In a move that indicates an escalation in its enforcement posture, the company said it has brought six new lawsuits related to alleged black-market distribution tied to its weight-loss drug candidate.

Lilly’s central message is that the products being marketed are not genuine, and that people who buy them face heightened risks. In remarks attributed to the company, Lilly’s chief marketing officer, Matt Hyman, said the items sold in the black market are “not a medicine.”

According to the report, Lilly characterized the products as unverified and unapproved. The company’s position, as described in the post, is that the black-market offerings have not been evaluated through the regulatory process required for legitimate medicines, and therefore should not be treated as safe or comparable to anything Lilly is developing and distributing through medical oversight.

The six additional lawsuits appear to be part of an ongoing effort to intervene earlier and more aggressively against unauthorized sellers. While the report does not lay out specific details such as the jurisdictions involved, the identities of the targets, or the exact claims in each case, it frames the actions as a response to continued off-channel activity.

Retatrutide is a drug program associated with metabolic and weight-management goals, and Lilly has been seeking to build a robust pipeline around related therapies. The company has repeatedly faced a broader industry challenge as demand for weight-loss and metabolic drugs has surged, including the risk that unauthorized products circulate while legitimate supply and clinical access remain constrained.

Why It Matters

  • More lawsuits suggest Lilly is trying to curb secondary-market activity rather than relying only on public warnings.
  • If unauthorized sellers continue to operate, the reputational and safety risk to legitimate drug programs can grow, even when the legal target is “gray” or counterfeit distribution.
  • Enforcement pressure can also shape how clinics and consumers respond to online or off-channel offers for weight-management drugs.

Sources

Key Facts

  • Eli Lilly said it filed six new lawsuits related to alleged black-market sales tied to retatrutide.
  • Matt Hyman, Lilly’s chief marketing officer, described the black-market products as “not a medicine.”
  • Lilly said the products being sold on the black market are unverified and unapproved.
  • The report frames the lawsuits as an escalation in Lilly’s effort to reduce exposure to unauthorized retatrutide offerings.

Healthcare Related

Aug 12, 2:09 AM EDT
The Apex Times

Pfizer agrees to $44 million settlement tied to Chantix class action

The U.S. drugmaker said it reached a class action resolution involving its smoking-cessation medicine Chantix, focused on allegations that safety-related disclosures were incomplete. The company also pointed to positive topline results from a separate late-stage study.

Pfizer agrees to $44 million settlement tied to Chantix class action
The Apex Times